

FIG. 1



FIG. 2A



FIG. 2B


p42
1 nM
10 µM
100 µM
Optical Density
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
5
10
15
20
Time (min)


p44
1 nM
10 µM
100 µM
Optical Density
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
5
10
15
20
Time (min)

FIG. 3


NECA
CPA
CGS
p42
p44
Optical Density
[NECA] (nmol/L)
0
1
10
100
1000
10000
50
150
200
250
0 1nM 10nM 100nM 1μM 10μM
p44
p42
NECA
CPA
CGS

FIG. 4


0
1 nM
10 nM
100 nM
1 μM
10 μM
NECA
p44
p42
ERK
CREB
Total
ERK
NECA
alone
+ PD98059
(50 μM)
+ H-89
(10 μM)
+ XAC
(10 μM)

FIG. 5


0 -8 -7 -6 -5 -4
log [NECA] (mol/L)
p44
p42
No Antagonist
p44
p42
Enprofylline
100 μM
p44
p42
JW V108
1 μM

FIG. 6


A2B Receptor Ribozyme
SEQ ID NO: 1)
SEQ ID NO: 2)
5' AGCUGGUCAUCGCC (nt 176-190)
3' UCGACCA UAGCGG
A CU
G
A
A U
G AG
C-G
G-C
G-C
C-G
G-C
G U
CU
0 1 2 3 4 5 10 30 60 120 180
Intact target
Cleaved target
Percent Target Cleaved
Time (min)
0 20 40 60 80 100 120 140
0 10 20 30 40 50 60 70 80 90

FIG. 7


Untreated
Sham
A2b Ribozyme
VEGF (pg/mL/10,000 cells)
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Incubation Time (days)


Untreated
Sham
A2b Ribozyme
Cells per Well (X 10,000)
18
16
14
12
10
8
6
4
2
0
0
1
2
3
4
5
6
7
Incubation Time (days)

FIG. 8


Fraction of Control (Uninjected)
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
*
*
Uninjected
Vehicle
Enprofylline
XAC
JWV-108

FIG. 9


Neovascular Nuclei per Sectior
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
Uninjected
IGF1 Rz2

FIG. 10

Consensus Hairpin ribozyme STRUCTURE:



N can be any ribonucleotide (A,C,G or U) and N' is the complementary nucleotide. Y is a pyrimidine. H is any nucleotide but guanosine (A, C or U). B is any nucleotide but adenosine (G,C or U). V is the complement of B (G, C or A).

FIG. 11

General hammerhead ribozyme structure:



FIG. 12